FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308334510> ?p ?o ?g. }

• W4308334510 endingPage "1629" @default.
• W4308334510 startingPage "1629" @default.
• W4308334510 abstract "Age-related macular degeneration AMD is one of the leading causes of blindness in the elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is implicated as the main attributor of visual loss among these patients. The hallmark feature of nAMD is the presence of neovascular structures known as choroidal neovascular membranes (CNVs), along with fluid exudation, hemorrhages, and subretinal fibrosis. These pathological changes eventually result in anatomical and visual loss. A type of proangiogenic factor known as vascular endothelial growth factor (VEGF) has been known to mediate the pathological process behind nAMD. Therefore, therapy has transitioned over the years from laser therapy that ablates the lesions to using Anti-VEGF to target the pathology directly. In this work, we provide an overview of current and emerging therapies for the treatment of nAMD. Currently approved Anti-VEGF agents include ranibizumab, aflibercept, and brolucizumab. Bevacizumab, also an Anti-VEGF agent, is used to manage nAMD even though this is an off-label use. While Anti-VEGF agents have provided a favorable prognosis for nAMD, they are associated with a substantial financial burden for patients and the healthcare system, due to their high cost as well as the need for frequent repeat treatments and visits. Emerging therapies and studies aim to extend the intervals between required treatments and introduce new treatment modalities that would improve patients' compliance and provide superior results." @default.
• W4308334510 created "2022-11-11" @default.
• W4308334510 creator A5017233177 @default.
• W4308334510 creator A5038227278 @default.
• W4308334510 creator A5062485196 @default.
• W4308334510 date "2022-11-03" @default.
• W4308334510 modified "2023-10-14" @default.
• W4308334510 title "Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration" @default.
• W4308334510 cites W1481978003 @default.
• W4308334510 cites W1500728559 @default.
• W4308334510 cites W1539571840 @default.
• W4308334510 cites W1543801259 @default.
• W4308334510 cites W1601975653 @default.
• W4308334510 cites W1629174936 @default.
• W4308334510 cites W1802218256 @default.
• W4308334510 cites W1837947864 @default.
• W4308334510 cites W1966486839 @default.
• W4308334510 cites W1968484708 @default.
• W4308334510 cites W1968609549 @default.
• W4308334510 cites W1971968805 @default.
• W4308334510 cites W1972242350 @default.
• W4308334510 cites W1973149924 @default.
• W4308334510 cites W1974327301 @default.
• W4308334510 cites W1976433015 @default.
• W4308334510 cites W1977141020 @default.
• W4308334510 cites W1982733715 @default.
• W4308334510 cites W1982983286 @default.
• W4308334510 cites W1985239012 @default.
• W4308334510 cites W1990424499 @default.
• W4308334510 cites W2001953460 @default.
• W4308334510 cites W2003324689 @default.
• W4308334510 cites W2004117352 @default.
• W4308334510 cites W2004196006 @default.
• W4308334510 cites W2005009598 @default.
• W4308334510 cites W2012906786 @default.
• W4308334510 cites W2020270194 @default.
• W4308334510 cites W2022878833 @default.
• W4308334510 cites W2033460602 @default.
• W4308334510 cites W2040457873 @default.
• W4308334510 cites W2045317893 @default.
• W4308334510 cites W2047657288 @default.
• W4308334510 cites W2054061193 @default.
• W4308334510 cites W2054621121 @default.
• W4308334510 cites W2057628931 @default.
• W4308334510 cites W2061213434 @default.
• W4308334510 cites W2075984382 @default.
• W4308334510 cites W2078326688 @default.
• W4308334510 cites W2085712747 @default.
• W4308334510 cites W2087780877 @default.
• W4308334510 cites W2088291107 @default.
• W4308334510 cites W2089092235 @default.
• W4308334510 cites W2091774189 @default.
• W4308334510 cites W2091989599 @default.
• W4308334510 cites W2115274617 @default.
• W4308334510 cites W2121286455 @default.
• W4308334510 cites W2124415048 @default.
• W4308334510 cites W2125587232 @default.
• W4308334510 cites W2127486928 @default.
• W4308334510 cites W2134161293 @default.
• W4308334510 cites W2149579095 @default.
• W4308334510 cites W2154073405 @default.
• W4308334510 cites W2157204458 @default.
• W4308334510 cites W2160726762 @default.
• W4308334510 cites W2164122959 @default.
• W4308334510 cites W2171962482 @default.
• W4308334510 cites W2172453889 @default.
• W4308334510 cites W2188489962 @default.
• W4308334510 cites W2223474822 @default.
• W4308334510 cites W2233259956 @default.
• W4308334510 cites W2396116581 @default.
• W4308334510 cites W2612675835 @default.
• W4308334510 cites W2647725203 @default.
• W4308334510 cites W2738996050 @default.
• W4308334510 cites W2740090310 @default.
• W4308334510 cites W2768578909 @default.
• W4308334510 cites W2804349267 @default.
• W4308334510 cites W2804532233 @default.
• W4308334510 cites W2807528781 @default.
• W4308334510 cites W2887429619 @default.
• W4308334510 cites W2905212259 @default.
• W4308334510 cites W2933377962 @default.
• W4308334510 cites W2936430874 @default.
• W4308334510 cites W2964556340 @default.
• W4308334510 cites W2981587847 @default.
• W4308334510 cites W3015836115 @default.
• W4308334510 cites W3043747921 @default.
• W4308334510 cites W3096802605 @default.
• W4308334510 cites W3101241490 @default.
• W4308334510 cites W3103660393 @default.
• W4308334510 cites W3121850306 @default.
• W4308334510 cites W3127111365 @default.
• W4308334510 cites W3135885187 @default.
• W4308334510 cites W3138940772 @default.
• W4308334510 cites W3147687651 @default.
• W4308334510 cites W3155919247 @default.
• W4308334510 cites W3158439775 @default.
• W4308334510 cites W3174604860 @default.
• W4308334510 cites W3200362086 @default.

• next